Proteasome inhibition has emerged as an important therapeutic strategy in multiple
myeloma (MM). Since the publication of the first phase 1 trials of bortezomib 10 years ago …

We conducted a systematic review to determine the appropriate use of bortezomib alone or
in combination with other agents in patients with multiple myeloma (MM). We searched …

Purpose We investigated whether bortezomib during induction and maintenance improves
survival in newly diagnosed multiple myeloma (MM). Patients and Methods In all, 827 …

In a randomized, phase 3 study, superior complete/near-complete response (CR/nCR) rates
and extended progression-free survival were demonstrated with bortezomib-thalidomide …

Abstract Treatment of multiple myeloma has evolved over the last decade, most notably with
the introduction of highly effective novel agents. It is now possible to aim for deep disease …

High-dose therapy plus autologous stem cell transplantation (ASCT) is considered the
standard of care for the frontline treatment in younger patients with multiple myeloma …

The management of multiple myeloma has undergone profound changes over the recent
past as a result of advances in our understanding of the disease biology as well as …

Proteasome inhibition has been shown to be an effective strategy for the treatment of
multiple myeloma, as demonstrated by the clinical activity of the first-in-class agent …

The treatment of newly diagnosed multiple myeloma has dramatically changed since the
emergence of proteasome inhibitors and immunomodulatory drugs. Front-line combination …

The introduction of the novel agents, thalidomide, bortezomib and lenalidomide as part of
the frontline induction both in transplant and non-transplant candidates have markedly …